Skip to Main Content

Drug Pricing May Return to HHS Agenda in 2018

Despite President Trump's pledge to rein in prescription drug pricing, the Administration did not take substantial action to address this issue in 2017. With the expected confirmation of Alex Azar – who is a former Eli Lilly executive – as the new Secretary of HHS, the Administration may initiate action. Azar has identified tackling high and rising drug costs as a top priority, stating that he would focus on competition, including a "robust generic market" and more competition for branded medicines and biosimilars. Azar has also targeted the "gaming of exclusivity and patents by branded drug companies."

Given Azar's background, we expect that CMS may provide guidance on value-based prescription drug purchasing and other innovative pricing ideas in 2018. CMS and CMMI may also promote new models of pricing and reimbursement for Part B drugs and Azar has indicated interest in expanding Medicare Part D/pharmacy benefit manager negotiation approaches into Part B.



Baker Donelson professional not admitted to the practice of law.

Email Disclaimer

NOTICE: The mailing of this email is not intended to create, and receipt of it does not constitute an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.
Cancel Accept